New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
Amgen stock was dropping in premarket trading after releasing what looked like positive data from a Phase 2 study for its ...
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares
Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% weight on average in a year-long ...
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen stock slips as obesity drug study disappoints Wall Street
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...
FierceBiotech4h
Amgen’s monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
BioPharma Dive1h
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data ...
STAT5h
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
Pacbiztimes.com50m
Amgen’s shares down after obesity drug fails to meet expectations
MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...